Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.69 |
| ▸ | RAF1 | P04049 | 16/20 | 0.66 |
| ▸ | FLT3 | P36888 | 4/20 | 0.66 |
| ▸ | ERN1 | O75460 | 3/20 | 0.66 |
| ▸ | ABL1 | P00519 | 3/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.66 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.66 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.66 |
| ▸ | HIPK1 | Q86Z02 | 3/20 | 0.66 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745887 | 0.93 | BRAF (0.59) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL2745257 | 0.90 | BRAF (0.83) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL2745874 | 0.90 | BRAF (0.67) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL3816773 | 0.89 | BRAF (0.56) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL2745462 | 0.89 | BRAF (0.74) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL3810951 | 0.89 | BRAF (0.65) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL3808850 | 0.88 | BRAF (0.59) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL3811132 | 0.88 | BRAF (0.59) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL3808827 | 0.88 | BRAF (0.64) | BRAFRAF1FLT3ERN1ABL1 | |
| SCHEMBL3817063 | 0.88 | BRAF (0.55) | BRAFRAF1FLT3ERN1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | claimed |
| EP-2013218-A2 | RAF INHIBITORS AND THEIR USES | ARQULE, INC. (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | claimed |
| WO-2007123892-A2 | RAF INHIBITORS AND THEIR USES | ARQULE INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2258704-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ArQule, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2013218-A2 | RAF INHIBITORS AND THEIR USES | ARQULE, INC. (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007123892-A2 | RAF INHIBITORS AND THEIR USES | ARQULE INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281955-A1 | RAF inhibitors and their uses | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885FLT3 80/4885 |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | MAPK1, MAPK14, MAPK15 | BRAF 181/4885RAF1 277/4885FLT3 474/4885 |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885FLT3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.